Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Abbott Milking More Profits By Imitating Baby Formula Business

Baby formula maker Mead's rising success has competitor Abbott Laboratories trying desperately to catch some of the momentum, which is showing no signs of slowing down.

Can Investors Diagnose Anything from Cancer Drug Summit?

The recently concluded American Society for Clinical Oncology is considered to be the landmark event where the biggest info is shared. So what was the news?

New AIDS Therapies May Shake Up Big Pharma Profits

Vaccines and transplants may usher in new players

Ziopharm Has Help With Deep Pockets

This biotech small-cap could soon be a cancer-drug player.

Should You Follow Icahn Into Amgen?

A study shows the mega-investor's targets deliver best when bought out.